In this episode, the focus is on the relationship between clinical outcomes, financial costs and societal impact. Dr Patrick Murphy explains the importance of collecting robust health economic data, using the example of the HOT-HMV trial that explored home NIV for COPD. If you’re interested in health economics, value-based healthcare, clinical commissioning or simply appreciate clear and informed discussion of a critical aspect of modern clinical research, you’ll want to tune in.

Guests:

• Dr Patrick Murphy - Lane Fox Respiratory Unit, Guy’s and St Thomas’ Hospital, London.

• Melike Deger-Wehr - Health Economics and Outcomes Research Director, ResMed.

Host:

• Nina Wiklund is ResMed’s Global Medical Marketing Content Lead, and has a burning enthusiasm for clinical research. She is especially interested in the additional insights and possibilities real-world evidence can add to existing RCTs. 

Disclaimers:

• This content is intended for health professionals only.
• This testimonial is a genuine and documented account of the individual’s response to treatment. Outcomes and results may vary, and this individual’s response does not provide any indication, warranty or guarantee that other people will have the same or a similar experience. This presentation is based on the professional presenter experience, practice and on recent available relevant data which is not intended to be understood as state of the art.
• Dr Patrick Murphy was provided with a nominal financial incentive for providing the following testimonial. Dr Patrick Murphy will not receive any discounts or further incentives as a result of this testimonial.

Listen to OnAir with Clinical Respiratory News, the podcast that brings you fresh insights and thought-provoking discussions about hot topics in respiratory care and sleep-disordered breathing.

© ResMed